Last reviewed · How we verify
S-equol
At a glance
| Generic name | S-equol |
|---|---|
| Also known as | AUS-131, Equelle, Equol |
| Sponsor | Ausio Pharmaceuticals, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition (PHASE2)
- Acute Equol Supplementation and Vascular Function in Women With and Without CKD (PHASE2)
- Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers (PHASE2)
- Equol and Vascular Function in Women With Chronic Kidney Disease (PHASE2)
- Polyphenol Metabolism and Personalized Nutrition in Menopause (PolyPause). (NA)
- Study of the Effects of Soy Exposure in Early Life on Bone Development and Gut Microbiota
- A Pilot Study to Evaluate Equol and Its Effects on Menopausal Symptoms Experienced by Women in Singapore
- Open-labelled Study to Evaluate the Effect of SE5-OH Tablets on Healthy Women With Menopausal Symptoms (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-equol CI brief — competitive landscape report
- S-equol updates RSS · CI watch RSS
- Ausio Pharmaceuticals, LLC portfolio CI